1. Australia Stocks

  2. •

    Technology services

  3. •

    Packaged software
HeraMED Ltd

HeraMED Ltd

AASX:HMD
0.04
AUD
+0.00
(+9.09%)
0.00EPS
38.53MMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.06
-0.05
-0.03
-0.04
-0.05
-0.04
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.07
0.03
0.02
- -
0.02
- -
- -
- -
Tangible Book Value per Share
0.05
0.02
0.01
-0.01
0.02
- -
- -
- -
Basic Weighted Avg Shares
89
90
129
178
219
266
532
1,070
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
1
- -
- -
Operating Margin (%)
-3,725.46
-2,221.15
-8,733.2
-4,545.68
-1,453.02
-1,100.13
-1,528.38
-1,228.15
Depreciation Expense
- -
- -
- -
- -
1
1
- -
- -
Net Income, GAAP
-5
-5
-4
-8
-11
-10
-5
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-4,880.82
-2,233.35
-8,500.28
-6,588.2
-2,229.48
-1,117.6
-1,507.04
-1,408.29
Working Capital
5
2
2
-1
5
- -
3
1
LT Debt
- -
- -
- -
- -
- -
- -
1
- -
Total Equity
6
3
3
- -
6
1
3
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-98.67
-149.64
- -
- -
-270.41
-290.78
-223.2

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-879.92%
-66.4%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
7.58%
-24.75%
Sales/Revenue/Turnover
- -
86.76%
-19.47%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.04
2024
- -
- -
-0.01
2025
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Anoushka Gungadin
Full Time Employees
17,000
Sector
Technology services
Industry
Packaged software
Address
117 Camberwell Road Hawthorn East VIC Australia 3123
IPO Date
Dec 4, 2018
Website
hera-med.com
Similar Companies
Microsoft Corporation (NASDAQ:MSFT)
Palantir Technologies Inc. (NASDAQ:PLTR)
Nebius Group N.V. (NASDAQ:NBIS)
Oracle Corporation (NYSE:ORCL)
CoreWeave, Inc. (NASDAQ:CRWV)
ServiceNow, Inc. (NYSE:NOW)
Business
HeraMED Limited (ASX:HMD) develops, manufactures and commercializes medically validated home-based maternity monitoring technologies including its core HeraBEAT fetal and maternal heart rate monitor and HeraCARE end-to-end digital maternity care platform featuring customizable care plans, full telehealth video/chat integration, remote patient monitoring, educational content, smart messaging and prenatal/postpartum support; the company reshapes doctor-patient relationships through cloud computing, artificial intelligence and big data to enable early risk detection, reduced in-office visits and improved care outcomes for low-risk and high-risk pregnancies including chronic hypertension, gestational diabetes and mental health conditions. Founded in 2011 and headquartered in Camberwell, Australia, with subsidiaries in Israel and the US, HeraMED targets healthcare providers, hospitals and clinics in Australia, the United States and Europe, generating revenue from HeraCARE deployments and HeraBEAT device sales under contracts with partners such as Broward Health, Telstra Health, Gold Coast University Hospital and PHI's Simply Women/JOGG clinics. Recent developments include a 2024 leadership transition with Anoushka Gungadin as CEO/Managing Director and Tim Chapman as Chairman alongside a four-point strategic plan emphasizing commercialization, partnerships and non-dilutive funding; key 2024 achievements feature the major HeraCARE rollout at Florida's Broward Health onboarding over 400 mothers across nine live care plans with 31,000 data measurements, $7.6 million capital raise via placements, letters of intent for US postpartum integration with Metronomic and EU interoperability with Founda Health, Spanish-language support launch, grant applications in Australia and Europe, and advisory board expansions with Vivek Krishnan, Cheryle Royle and Sharon Howell; in November 2025 HeraMED announced a partnership with Philips for US maternity solutions furthering its digital health ecosystem integration.